



KAISER PERMANENTE®

Mid-Atlantic States

## Endobronchial Valve

### Medical Coverage Policy

---

#### UTILIZATION \* ALERT\*

- Prior to use of this MCP for evaluation of medical necessity, benefit coverage MUST be verified in the member's EOC or benefit document.
- For Medicare members, please refer to CMS guidelines through Medicare Coverage Database requirements.
- Medicare currently does not have a National Coverage Determination (NCD) for Endobronchial Valves.
- Local coverage determinations (LCD)/Local Coverage Articles (LCA) do not exist at this time.
- If no NCD/LCD/LCA is found, please use this KP-MAS Medical Coverage Policy.

---

#### I. Procedure: Endobronchial Valve

#### II. Specialty: Pulmonary Medicine

#### III. Definition

**Endobronchial Valve** is an endobronchial implant designed to occlude a hyperinflated lobe of the lungs with multiple valves, allowing air to escape while blocking airflow into the treated lobe to reduce lung volume and hyperinflation in the targeted area.

#### IV. Indications for Referral

Endobronchial valve is indicated for bronchoscopic treatment of adult patients when ALL of the following are present:

- A. Hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation;
- B. Have not responded to conventional medical management such as bronchodilators, corticosteroids, antibiotics, or anti-inflammatory maintenance medications; **and**
- C. Lung surgery such as lung volume reduction or lung transplant is not suitable or appropriate.

#### V. Exclusions and Limitations

A. An endobronchial valve is **contraindicated** for the following condition:

1. Evidence of active lung infection;
2. Known allergies to nitinol (nickel-titanium), nickel, titanium, or silicone;
3. Active smokers or have not quit smoking;
4. Diagnosed with large bullae encompassing greater than 30% of either lung;
5. Inability to tolerate bronchoscopic procedures; or
6. Bronchoscopic procedures are contraindicated.

#### B. Precaution

Caution and appropriateness of endobronchial valve treatment should be discussed when the patient has any of the following:



KAISER PERMANENTE®

Mid-Atlantic States

## Endobronchial Valve

### Medical Coverage Policy

1. Major lung procedures;
2. Heart disease;
3. Large bubbles of air trapped in the lung; *or*
4. Have not responded to other treatments

#### References

1. A Du Rand, P V Barber, J Goldring, R A Lewis, S Mandal, M Munavvar, R C Rintoul, P L Shah, S Singh, M G Slade, A Woolley. British Thoracic Society Guideline for Advanced Diagnostic and Therapeutic Flexible Bronchoscopy in Adults. on behalf of the British Thoracic Society Interventional Bronchoscopy Guideline Group. *Thorax* 2011 Volume 66, Issue Suppl 3: iii1-iii21 doi: 10.1136/thoraxjnl-2011-200713. [https://thorax.bmj.com/content/thoraxjnl/suppl/2011/10/10/thoraxjnl-2011-200713.DC1/Appendix\\_4.pdf](https://thorax.bmj.com/content/thoraxjnl/suppl/2011/10/10/thoraxjnl-2011-200713.DC1/Appendix_4.pdf) or [https://thorax.bmj.com/content/66/Suppl\\_3/iii1](https://thorax.bmj.com/content/66/Suppl_3/iii1)
2. JE van Agteren JE, Hnin K, Grosser D, et al. Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. Feb 23 2017;2:CD012158. PMID 28230230. <https://www.ncbi.nlm.nih.gov/pubmed/28230230>
3. Riise G, Svanberg T, Samuelsson O. Lakartidningen. Severe COPD can Benefit from Endobronchial Valves. *Lakartidningen* 2019 May 28;116. pii: FLM3. PMID: 31192398 <https://www.ncbi.nlm.nih.gov/pubmed/31192398>
4. Yu WC, Kwok HC, Chan YH, Ho MY, Chan MC, Yeung YC. Endobronchial one-way valve for persistent air leak and lung volume reduction. *Respirol Case Rep*. 2019 Jul 15;7(7):e00461. doi: 10.1002/rcr2.461. eCollection 2019 Oct. PMID: 31341625 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629543/>
5. Dirk-Jan Slebos, Pallav L. Shah, Felix J.F. Herth and Arschang Valipoure. Endobronchial Valves for Endoscopic Lung Volume Reduction: Best Practice Recommendations from Expert Panel on Endoscopic Lung Volume Reduction. *Respiration*. 2017;93(2):138-150. doi: 10.1159/000453588. Epub 2016 Dec 20. DOI: [10.1159/000453588](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363212/) <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363212/>
6. Bermea RS, Miller J, Wilson WW, Dugan K, Frye L, Murgu S, Hogarth DK. [One-Way Endobronchial Valves as Management for Persistent Air Leaks: A Preview of What's to Come?](https://www.atsjournals.org/doi/pdf/10.1164/rccm.201904-0761LE) *Am J Respir Crit Care Med*. 2019 Jul 16. doi: 10.1164/rccm.201904-0761LE. PMID: 31310162 <https://www.atsjournals.org/doi/pdf/10.1164/rccm.201904-0761LE>
7. Kristiansen JF, Perch M, Iversen M, Krakauer M<sup>4</sup>, Mortensen J. Lobar Quantification by Ventilation/Perfusion SPECT/CT in Patients with Severe Emphysema Undergoing Lung Volume Reduction with Endobronchial Valves. *Respiration*. 2019 Jun 5:1-9. doi: 10.1159/000500407 <https://www.karger.com/Article/Abstract/500407>
8. Valipour A. Valve therapy in patients with emphysematous type of chronic obstructive pulmonary disease (COPD): from randomized trials to patient selection in clinical practice. *J Thorac Dis*. 2018 Aug; 10(Suppl 23): S2780–S2796. doi: [10.21037/jtd.2018.08.86](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129808/) <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129808/>



KAISER PERMANENTE®

Mid-Atlantic States

## Endobronchial Valve

### Medical Coverage Policy

9. Li Yang, Kelvin Hsu, Jonathan P. Williamson, Matthew J. Peters, Kevin Ho-Shon, Alvin J. Ing. Changes in ventilation and perfusion following lower lobe endoscopic lung volume reduction (ELVR) with endobronchial valves in severe COPD. *Clin Respir J*. 2019 Jul;13(7):453-459. doi: 10.1111/crj.13031. Epub 2019 May 15. <https://www.ncbi.nlm.nih.gov/pubmed/31006169> or <https://doi.org/10.1111/crj.13031>
10. U.S. Food & Drug Administration FDA Approves Novel Device for Treating Breathing Difficulty from Severe Emphysema. June 29, 2018. <https://www.fda.gov/news-events/press-announcements/fda-approves-novel-device-treating-breathing-difficulty-severe-emphysema>
11. Gerard J. Criner, Richard Sue, Shawn Wright, Mark Dransfield, Hiram Rivas-Perez, Tanya Wiese, Frank C. Sciruba, Pallav L. Shah, Momen M. Wahidi, Hugo Goulart de Oliveira, Brian Morrissey, Paulo F. G. Cardoso, Steven Hays, Adnan Majid, Nicholas Pastis, Jr., Lisa Kopas, Mark Vollenweider, P. Michael McFadden, Michael Machuzak, David W. Hsia, Arthur Sung, Nabil Jarad, Malgorzata Kornaszewska, Stephen Hazelrigg, Ganesh Krishna, Brian Armstrong, Narinder S. Shargill, and Dirk-Jan Slebos for the **LIBERATE Study Group**. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). *Am J Respir Crit Care Med* Vol 198, Iss 9, pp 1151–1164, Nov 1, 2018 Copyright ©2018 by the American Thoracic Society. DOI: [10.1164/rccm.201803-0590OC](https://doi.org/10.1164/rccm.201803-0590OC) <https://www.atsjournals.org/doi/full/10.1164/rccm.201803-0590OC>.
12. Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, Broman G, Hillerdal G, Mal H, Pison C, Briault A, Downer N, Darwiche K, Rao J, Hübner RH, Ruwwe-Glosenkamp C, Trosini-Desert V, Eberhardt R, Herth FJ, Derom E, Malfait T, Shah PL, Garner JL, Ten Hacken NH, Fallouh H, Leroy S, Marquette CH; TRANSFORM Study Team. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (**TRANSFORM**). *Am J Respir Crit Care Med*. 2017 Dec 15;196(12):1535-1543. doi: 10.1164/rccm.201707-1327OC. <https://clinicaltrials.gov/ct2/show/NCT02022683>
13. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (2019) Available at: <https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf>.
14. National Institute for Health and Care Excellence. Endobronchial valve insertion to reduce lung volume in emphysema. <https://www.nice.org.uk/guidance/IPG600/chapter/1-Recommendations>. <https://www.nice.org.uk/guidance/ng115>
15. U.S. Food & Drug Administration. Spiration Valve System. Summary of Safety and Effectiveness Data. Available at: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf18/P180007B.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180007B.pdf).
16. Skowasch, D., Fertl, A., Schwick, B., Schäfer, H., Hellmann, A., Herth, F. J., & LIVE Study Investigators (2016). A Long-Term Follow-Up Investigation of Endobronchial Valves in Emphysema (the LIVE Study): Study Protocol and Six-Month Interim Analysis Results of a Prospective Five-Year Observational Study. *Respiration; international review of thoracic diseases*, 92(2), 118–126. <https://doi.org/10.1159/000448119>
17. Li, S., Wang, G., Wang, C., Gao, X., Jin, F., Yang, H., Han, B., Zhou, R., Chen, C., Chen, L., Bai, C., Shen, H., Herth, F., & Zhong, N. (2019). The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema. *Respiration; international review of thoracic diseases*, 97(5), 416–427.



KAISER PERMANENTE®

Mid-Atlantic States

## Endobronchial Valve

### Medical Coverage Policy

<https://doi.org/10.1159/000494327>

18. Dransfield, M. T., Garner, J. L., Bhatt, S. P., Slebos, D. J., Klooster, K., Sciruba, F. C., Shah, P. L., Marchetti, N. T., Sue, R. D., Wright, S., Rivas-Perez, H., Wiese, T. A., Wahidi, M. M., Goulart de Oliveira, H., Armstrong, B., Radhakrishnan, S., Shargill, N. S., Criner, G. J., & LIBERATE Study Group: (2020). Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial. *Annals of the American Thoracic Society*, 17(7), 829–838. <https://doi.org/10.1513/AnnalsATS.201909-666OC>.
19. Nada, K. M., & Nishi, S. (2020). Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials. *Mayo Clinic proceedings. Innovations, quality & outcomes*, 5(1), 177–186. <https://doi.org/10.1016/j.mayocpiqo.2020.09.009>
20. Klooster, K., Valipour, A., Marquette, C. H., Boutros, J., Mal, H., Marceau, A., Shah, P. L., Conway, F., Deslée, G., Bourdin, A., Pison, C., Grah, C., Hetzel, M., Schumann, C., Kessler, R., Huebner, R. H., Skowasch, D., Darwiche, K., Hammerl, P., Stanzel, F. Slebos, D. J. (2021). Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema. *Respiration; international review of thoracic diseases*, 1–7. Advance online publication. <https://doi.org/10.1159/000515744>
21. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: Diagnosis and management. Available at: <https://www.nice.org.uk/guidance/ng115>. Accessed 05/10/2022
22. Kemp, S. V., Slebos, D. J., Kirk, A., Kornaszewska, M., Carron, K., Ek, L., Broman, G., Hillerdal, G., Mal, H., Pison, C., Briault, A., Downer, N., Darwiche, K., Rao, J., Hübner, R. H., Ruwwe-Glosenkamp, C., Trosini-Desert, V., Eberhardt, R., Herth, F. J., Derom, E., ... TRANSFORM Study Team \* (2017). A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). *American journal of respiratory and critical care medicine*, 196(12), 1535–1543. <https://doi.org/10.1164/rccm.201707-1327OC>
23. Criner, G. J., Delage, A., Voelker, K., Hogarth, D. K., Majid, A., Zgoda, M., Lazarus, D. R., Casal, R., Benzaquen, S. B., Holladay, R. C., Wellikoff, A., Calero, K., Rumbak, M. J., Branca, P. R., Abu-Hijleh, M., Mallea, J. M., Kalhan, R., Sachdeva, A., Kinsey, C. M., Lamb, C. R., ... Martel, S. (2019). Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. *American journal of respiratory and critical care medicine*, 200(11), 1354–1362. <https://doi.org/10.1164/rccm.201902-0383OC>

 <b>KAISER PERMANENTE</b> <sup>®</sup> Mid-Atlantic States	<b>Endobronchial Valve</b> <b>Medical Coverage Policy</b>
---	--

**Approval History**

Effective June 01, 2016, state filing is no longer required per Maryland House Bill [HB 798](#) – Health Insurance – Reporting

Date approved by RUMC*	Date of Implementation
10/29/2019	10/29/2019
10/15/2020	10/15/2020
10/19/2021	10/19/2021
10/20/2022	10/20/2022
09/27/2023	09/27/2023
09/26/2024	09/26/2024

\*The Regional Utilization Management Committee received delegated authority in 2011 to review and approve designated Utilization Management and Medical Coverage Policies by the Regional Quality Improvement Committee.

Note: Kaiser Permanente Mid-Atlantic States (KPMAS) include referral and authorization criteria to support primary care and specialty care practitioners, as appropriate, in caring for members with selected conditions. Medical Coverage Policies are not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by a practitioner in any particular set of circumstances for an individual member.

©2024, Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc.  
 ©2024, Mid-Atlantic Permanente Medical Group, P.C.